Brolucizumab: First Approval
Sign Up to like & getrecommendations! Published in 2019 at "Drugs"
DOI: 10.1007/s40265-019-01231-9
Abstract: Brolucizumab (Beovu®) is a low molecular weight, single-chain antibody fragment vascular endothelial growth factor (VEGF) inhibitor being developed by Novartis for the treatment of exudative (wet) age-related macular degeneration (AMD), diabetic macular oedema and macular… read more here.
Keywords: first approval; brolucizumab first; approval;